Synovectomy during total knee arthroplasty: a pilot single-centre randomised controlled trial. by Rankin KS et al.
RESEARCH Open Access
Synovectomy during total knee
arthroplasty: a pilot single-centre
randomised controlled trial
Kenneth S. Rankin1* , Jayasree Ramaskandhan1, Michelle Bardgett1, Katie Merrie1, Rajkumar Gangadharan1,
Ian Wilson2 and David Deehan1
Abstract
Background: Total knee arthroplasty (TKA) is an effective procedure for late-stage osteoarthritis (OA) of the knee;
however, up to 20% of patients remain dissatisfied. In some patients, this may be due to residual inflammation of
the synovium. Our aim was to perform the first randomised controlled trial (RCT) of synovectomy during TKA for
patients with macroscopically inflamed synovium. The main objectives were to assess recruitment rates, protocol
adherence and outcomes relating to safety such as haemoglobin decrease and adverse events. We also collected
data on patient-reported outcomes.
Methods: We performed a single-centre pilot RCT. Patients with a macroscopically inflamed synovium were
randomised to receive synovectomy versus a control group that did not undergo synovectomy. We determined
feasibility by measuring patient enrolment, completeness of follow-up, and safety via haemoglobin decrease and
documentation of adverse events.
Results: We screened 360 patients with 260 deemed ineligible or could not be recruited. From the 100 eligible
patients, 54 were enrolled and 40 progressed through to randomisation. All made it to the 12-month follow-up,
indicating good protocol adherence. There were no major differences in adverse events or haemoglobin decrease
demonstrating acceptable safety. Outcomes relating to satisfaction were reliably obtained.
Conclusions: Patients with macroscopically inflamed synovium of the knee who are due to undergo TKA can be
reliably recruited to a randomised trial and synovectomy can be performed safely. A large number is needed to be
screened to identify eligible participants, and therefore, a multi-centre trial would be required to assess whether
routine synovectomy would improve outcomes in these patients.
Trial registration: ISRCTN, ISRCTN31010214. Registered 6 October 2016—retrospectively registered
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Background
Osteoarthritis (OA) is the most common disease affect-
ing synovial joints in the middle- to old-age population
[1]. The knee is one of the most frequent anatomical lo-
cations involved, which results in a massive health eco-
nomic burden related to physical disability [2].
Late-stage osteoarthritis of the knee is defined as severe
pain not controlled with regular analgesic medication
accompanied by radiographic evidence of joint space
narrowing, osteophyte formation and subchondral scler-
osis. Due to a complete lack of disease-modifying osteo-
arthritis agents, surgery in the form of total knee
arthroplasty (TKA) remains the most effective method
of managing late-stage cases [3]. There are an increasing
number of patients receiving TKA which is due to im-
proving knee implant designs and a lowering of thresh-
olds for surgeons to offer surgery [4]. In the UK, over
85,000 patients undergo TKA each year [5], and in the
USA, this figure is over 620,000 [6]. With the economic
impact of the projected 56,918 patients requiring
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revision surgery which is due to reach $2 billion annu-
ally by 2030, any reduction in the requirement for fur-
ther procedures would be welcome [7].
Survival for most implant designs with revision taken
as an endpoint is over 95% at 10 years; however, satisfac-
tion analyses indicate consistently that at least 20% of
patients are dissatisfied with their knee replacement [8].
The variability in macroscopic appearance of the syno-
vium has been noted by surgeons performing TKA [9],
and the historical description of OA as a
non-inflammatory disease has been superseded by clin-
ical [10], radiological [11–14], and pathological [15] evi-
dence of inflammatory processes, particularly in the
knee joint. There is concern, therefore, that a proportion
of patients reporting unsatisfactory outcomes following
TKA may have persistent inflammatory activity in the
knee joint driven by the presence of residual synovitis
[16]. There have been three surgical trials assessing
synovectomy during TKA. All concluded there is no
benefit to performing synovectomy; however, in all of
these studies, there was no intra-operative attempt to
discriminate between inflamed and non-inflamed syno-
vium [17–19].
Our aim was to perform the first randomised con-
trolled trial (RCT) of synovectomy versus no synovect-
omy during TKA for OA in patients with
macroscopically inflamed synovium. The main objectives
were to assess recruitment rates, protocol adherence,
and outcomes relating to safety such as haemoglobin de-
crease and adverse events. We also collected data on
patient-reported outcomes.
Methods
Study design and setting
Ethical approval was obtained (Regional Ethics Commit-
tee reference: 10/H0904/76) followed by permission
from our local Research Governance Department. The
study set up commenced in June 2013, and final
follow-up was in October 2015. Participants were re-
cruited between 1 November, 2013, and 7 October, 2014.
The study was performed at a university hospital in the
UK. Forty patients who are due to undergo a routine
primary total knee arthroplasty (TKA) procedure under
the care of three senior surgeons completed participa-
tion in the study. The study is registered to the ISRCTN:
31010214. The schedule of the trial (Additional file 1) is
available as supplementary material.
Participants/study subjects
Inclusion criteria were patients over the age of 18 years
with a diagnosis of late-stage knee osteoarthritis. Exclu-
sion criteria were as follows: refusal or inability to pro-
vide informed consent; those unable to answer
questionnaires for cognitive reasons; patients diagnosed
with auto-immune inflammatory arthritis of the knee;
morbidly obese individuals (with BMI > 40); patients
with a neuromuscular disorder that would affect their
ability to mobilise; patients undergoing bilateral syn-
chronous knee replacement procedures; patients under-
going more complex surgery requiring an implant with
increased constraint including posterior cruciate sacri-
ficing designs. Written consent was obtained from those
agreeing to participate.
Randomisation and blinding
The trial consisted of two arms, and randomisation was
performed intra-operatively by a research nurse attend-
ing the operating room. After eversion of the patella, the
synovium was evaluated by the surgeon. Evidence of
hyperplasia, papilla formation and engorgement was de-
fined as being consistent with a macroscopically in-
flamed synovium and deemed an inclusion criterion
(Fig. 1). Patients who did not have a macroscopically in-
flamed synovium underwent a standard surgical
Fig. 1 Representative photographs of non-inflamed versus inflamed synovium. a Synovium that is not macroscopically inflamed. Black arrows: on
the knee. Inset: small representative specimen. Patient is withdrawn from the study. b Synovium that is macroscopically inflamed. White arrows:
on the knee. Inset: small representative specimen. Patient is randomised intra-operatively
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procedure and were withdrawn from the study. Partici-
pants with confirmed macroscopically inflamed syno-
vium were randomised to receive synovectomy or no
synovectomy and underwent a standard implantation of
the prosthesis. Participants were blinded until their
1-year follow-up. Block randomisation was performed by
a research nurse using the ‘sealed envelope.com’ website
to provide the allocation until 20 participants had been
recruited into each arm. The research nurse was not in-
volved in any further aspects of the trial.
Interventions
All operations were performed using a standard surgical
approach with prior application of a high thigh tourniquet.
The procedure consisted of a midline incision, a medial
parapatellar approach and eversion of the patella. Hoffa’s
fat pad in all cases was excised to facilitate access to the
joint. A cemented cruciate retaining implant was used in
all cases. No patients received tranexamic acid. Antibiotic
and thromboprophylaxis protocols were identical for both
groups, and post-operative rehabilitation was the same.
For participants randomised to synovectomy, a meticulous
technique was undertaken to avoid significant blood loss.
This involved resection of the intimal and subintimal
layers, leaving the vascular layer intact.
Follow-up
Our team of research physiotherapists followed partici-
pants at 6 weeks and 1 year to document clinical out-
comes and patient-reported outcome measures. In
addition, haemoglobin decrease day 1 post-operatively
was documented. The clinical outcome measure was im-
provement in range of movement assessed
pre-operatively and at 6 weeks and 1 year
post-operatively. The patient-reported outcome mea-
sures evaluated included disease orientated, satisfaction
and general quality of life scores. The Western Ontario
and McMaster Universities osteoarthritis index
(WOMAC) provides general information about the im-
pact of the disease process on daily life [20] and was
measured pre-operatively and 1 year post-operatively. A
score for patient-reported co-morbid medical conditions
was included to demonstrate that there were no partici-
pants with a disease process other than OA that would
hinder their rehabilitation [21]. The Short Form 36
health survey (SF-36) [22], and EQ-5D [23] are general
quality of life scores which have been demonstrated to
improve following successful TKA and were therefore
measured pre-operatively and 1 year post-operatively. Fi-
nally, a patient satisfaction from surgery score was ob-
tained using a validated outcome measure [24]; this
questionnaire includes four questions about satisfaction
with overall outcome, pain relief, ability to perform ac-
tivities of daily living and ability to participate in leisure
Table 1 Attrition from screening to enrolment
360 screened
196 ineligible
46 listed for surgery under private healthcare
37 listed for revision rather than primary TKA
27 due to undergo bilateral synchronous TKA
24 not a participating surgeon
23 auto-immune inflammatory joint disease
16 BMI > 40
8 co-existent medical problem
4 screened before official study start date
3 inability to provide informed consent
3 listed for NHS waiting list Saturday surgery
2 cognitive reasons
2 not listed for primary TKA
1 fixed motor deficit
164 initially eligible but 22 not given study information or
approached
15 recruitment closed
7 surgery time changed so unable to approach
142 were sent a patient information sheet and 42 had no further
contact or approach
10 recruitment had closed
8 surgery cancelled or time changed
7 surgeon not participating
7 no staff available to approach
3 listed for NHS waiting list Saturday surgery
3 discovered BMI > 40
2 listing changed to private healthcare
1 fixed motor deficit
1 deceased
100 patients contacted or approached: 21 declined and 25 discovered
ineligible
8 surgeon not participating
5 surgery cancelled or time changed
3 listed for bilateral synchronous TKA
3 discovered BMI > 40
2 inability to provide informed consent
1 fixed motor deficit
1 listed for complex TKA
1 listing changed to private healthcare
1 listed for NHS waiting list Saturday surgery
54 enrolled
14 withdrawn due to intra-operative finding of non-inflamed
synovium
40 randomised and followed up
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activities. Responses are on a 4-point Likert scale, which
ranges from very satisfied to very dissatisfied. The satis-
faction score was measured at 1 year post-operatively.
Complications were recorded using a standard proforma.
Participants were given a telephone helpline number to
contact the study team in the event of any adverse
events. In addition, at the 6-week follow-up, the research
team actively sought out any possible adverse events
from the participants.
Statistical analyses
A sample size was not calculated due to the design of
the study, i.e. pilot trial. The aim was to screen, enrol
and randomise as many patients as possible over a
12-month recruitment period and stop recruitment
when 20 to 30 patients were enrolled into each arm.
Statistical analysis was performed on the clinical range
of movement data to assess for improvement from the
6-week to 1-year time points which should be demon-
strable in a small TKA group and also to assess for a dif-
ference between the intervention and no intervention
groups. An analysis was also performed to check for a
significant difference in haemoglobin decrease between
the intervention and no intervention groups. The ana-
lysis was performed using SPSS software version 17
(SPSS Inc., Chicago, IL). The data were checked for nor-
mal distribution using the Kolmogorov-Smirnov test.
The two sample t test was used for comparison of means
for the SF-36, WOMAC and EQ-5D scores. Results are
presented with 95% confidence intervals, and any hy-
pothesis testing is preliminary and should be interpreted
with caution.
Results
Recruitment
The participants were recruited between 1 November,
2013, and 7 October, 2014. Three hundred sixty patients
were screened. Two hundred sixty were found to be in-
eligible or could not be recruited. Fifty-four of the eli-
gible patients agreed to participate, and informed
consent was obtained. A detailed summary of the attri-
tion from screening is shown in Table 1.
Fourteen participants were subsequently withdrawn
due to the finding of a non-inflamed synovium
intra-operatively. Twenty participants were randomised
to each group. Of the 40 participants, all were success-
fully followed up to the 1-year conclusion with no drop
outs, as per the CONSORT diagram (Fig. 2).
Baseline characteristics
There were 40 patients in the study with 20 participants
in each arm (Table 2). There were 29 males and 11
Fig. 2 CONSORT flow chart
Table 2 Baseline characteristics of the participants according to
intervention
No synovectomy (n =
20)
Synovectomy (n =
20)
Sex
Male, n (%) 13 (65%) 16 (80%)
Female, n (%) 7 (35%) 4 (20%)
Age in years (range) 67.5 (44.6–83.3) 69.1 (54.6–85.4)
Average number of
co-morbidities mean (SD)
1.4 (1.1) 1.5 (1.4)
Side of operation
Right, n (%) 12 (60%) 7 (35%)
Left, n (%) 8 (40%) 13 (65%)
BMI (kg/m2) mean
(SD)
28.7 (3.2) 30.1 (3.4)
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females. Mean age was 67.5 for the no synovectomy
group and 69.1 for the synovectomy group.
Safety
There was a decrease in mean haemoglobin levels ob-
served in both groups from pre-operatively to day one
post-operatively: no synovectomy 138 g/L (SD 14) to
118 g/L (SD 16) versus synovectomy 141 g/L (SD 11) to
117 g/L (SD 10). There was no difference in mean
haemoglobin levels between the two groups both
pre-operatively relative risk − 2.90, 95% CI − 10.9 to 5.1,
p = 0.467, and post-operatively relative risk 0.30, 95% CI
− 8.36 to 8.96, p = 0.944. No patient received a blood
transfusion.
There were 10 adverse events reported during the
study (Table 3). Two were serious adverse events due to
hospitalisation of the participants, both of whom were in
the synovectomy group. In one case, this was due to
constipation, and in the second case, the participant had
developed a superficial wound infection. This was
treated with antibiotics only and did not require surgical
intervention. These serious adverse events were not clas-
sified as related to the synovectomy procedure.
Feasibility
All 40 randomised patients completed follow-up to the
1-year end point. There was 100% documentation of
range of movement scores at all time points.
For the patient-reported outcome measures, complete-
ness of follow-up was 100% for the EQ-5D, 95% for the
WOMAC and SF-36 scores and 87.5% for the patient
satisfaction from surgery scores (Table 4). The loss of
data was due to illegible recording on the scoresheet by
the participants. There were no protocol deviations.
Secondary outcomes
There was no difference in range of movement within
the groups from pre-operatively to 1 year
post-operatively (p = 0.602). There was a significant im-
provement in knee range of motion from 6 weeks
post-operatively to 1 year post-operatively for both
groups (no synovectomy: 100.5° (SD 14.1) to 113.8° (SD
12.6), p < 0.0001; synovectomy: 97.5° (SD 12.5) to 114.2°
(SD 11.4), p < 0.0001). For the EQ-5D Health score, the
no synovectomy group scored lower than the synovect-
omy group at 1 year (81.00 versus 85.63), but this did
not achieve statistical significance (Table 5).
There was a significant improvement in mean SF-36
scores from pre-operative to 1 year post-operatively for
all domains (p < 0.0001) within both groups. There was
no statistically significant difference between the groups
at the 1-year follow-up (Table 6).
There was a significant improvement in mean
WOMAC scores for the no synovectomy group (pain
39.7 (SD 15.3) to 78.6 (SD 21.0); function 40.3 (SD 19.3)
to 74.3 (SD 23.3); stiffness 40.1 (SD 21.4) to 76.3 (SD
19.5); p < 0.0001) and the synovectomy group (pain 43.6
(SD 15.0) to 83.9 (SD 21.2); function 48.1 (SD 11.6) to
84.6 (SD 16.6); stiffness 50.0 (SD 18.1) to 80.1 (SD 15.3);
p < 0.0001). There was no significant difference between
groups in mean WOMAC scores for pain (p = 0.448),
function (p = 0.131) and stiffness (p = 0.531) at 1 year
post-operatively (Table 7).
There was no difference between groups in terms of
patient satisfaction reported for pain relief (synovectomy
group 94.1% vs control group 88.9%; proportion differ-
ence = 5.2%, 95% CI 63% to 98%), return to activities of
daily living (ADL) (synovectomy group 83.4% vs control
group 88.5%; proportion difference = 5.1%, 95% CI 60%
to 90%), return to recreational activities (synovectomy
group 77.8% vs control group 100%; proportion differ-
ence = 22.2%, 95% CI 54% to 91%) and overall satisfac-
tion from surgery (synovectomy group 89.9% vs control
Table 3 All adverse events
No synovectomy
(n = 20)
Synovectomy
(n = 20)
Total adverse events 3 7
Serious adverse events
Death 0 0
Life threatening 0 0
Admission to hospital 0 1
Constipation Resolved with laxatives
Admission to hospital 0 1
Superficial wound
infection
Resolved with
antibiotics
Adverse events
Suspected DVT
(excluded)
1 2
Suspected DVT
(confirmed)
0 0
Hip pain 1 0
Nausea 0 1
Wound problem 1 1
Urinary tract infection 0 1
Table 4 Completeness of follow-up
Outcome Pre-operative, n (%) 6 weeks, n (%) 1 year, n (%)
Range of movement 40 (100) 40 (100) 40 (100)
WOMAC 38 (95) n/a 38 (95)
SF-36 38 (95) n/a 38 (95)
EQ-5D 40 (100) n/a 40 (100)
Satisfaction score n/a n/a 35 (87.5)
WOMAC Western Ontario and McMaster Universities Arthritis Index, SF-36 Short
form 36, EQ-5D Euroqol Five Dimension Scale
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group 93.8%; proportion difference = 3.9%, 95% CI 67%
to 96%) at 1 year post-operatively (Figs. 3 and 4).
Discussion
The evidence of an inflammatory component of knee
OA at the early to late stages of disease is increasing
and can even be tracked systemically [25]. At the
knee joint, apart from the synovium, there are studies
indicating that other tissues such as the fat pad can
be a source of inflammation [26]. Furthermore, gen-
omic studies of various joint tissue types from pa-
tients with knee OA have implicated epigenetic
effects that result in the upregulation of
pro-inflammatory cytokines [27] and the link from in-
flammation to the stimulation of pain pathways in
knee OA is well established [28]. From a clinical per-
spective, a case series of arthroscopic debridement
and synovectomy in the moderate to severe stages of
knee OA has shown some benefit; however, this was
temporary due to the progressive nature of the path-
ology [29]. Therefore, TKA remains the treatment of
choice for late-stage disease but the significant pro-
portion of dissatisfied patients continues to be a chal-
lenge. The aim of future therapy for knee OA should
include accurate identification of those patients who
are at risk of residual pain due to persistent inflam-
mation in the soft tissues following TKA. This would
involve assessing clinical, radiological and possibly
systemic parameters to define the level of inflamma-
tion in the joint prior to embarking on therapy. There
have been three randomised controlled trials that
have sought to assess the effect of synovectomy dur-
ing TKA [17–19]. In one of these studies, patients
with clinical evidence of synovial thickening were in-
cluded, but there was no mention of the state of the
synovium intra-operatively [18]. The other two studies
made no attempt to assess levels of inflammation in
the joint [17, 19]. These trials did not discern any
benefit from synovectomy, and in two studies, there
was evidence of increased blood loss in the interven-
tion group [17, 19]. In one of these trials [17], the
participants received bilateral synchronous knee re-
placements with one side randomised to undergo
synovectomy. Blood loss was 107 cc higher in the
synovectomy patients, and this did not impact on
outcomes. It should be noted that the surgical tech-
nique for synovectomy was described in only one of
these trials which entailed resection of all the syn-
ovial layers, including the vasculature [18]. This is
important, because an accurate synovectomy tech-
nique that removes the subintimal and intimal layers
but leaves the vascular layer intact will result in
minimal haemorrhage if the precise tissue planes are
identified and respected. In our study, we rando-
mised the participants intra-operatively after con-
firmation of the macroscopically inflamed synovium
and performed a meticulous synovectomy technique
retaining the vascular layer. Our trial demonstrates
that synovectomy can be performed safely in patients
with evidence of synovitis with no detrimental ef-
fects. We have also demonstrated that the enrolled
participants could be followed up reliably up to
1 year post-operatively with documentation of ad-
verse events and patient-reported outcome measures.
In keeping with the difficulties experienced in
recruiting to surgical RCTs in general, our study re-
veals a high rate of attrition from screening to enrol-
ment with a wide range of reasons for eligible
patients not making it to the consent stage. This is
Table 5 EQ-5D pre-operatively and 1 year post-operatively.
Numbers are mean (SD)
No synovectomy Synovectomy 95% CI
Pre-operative n = 20
77.55 (17.57)
n = 20
77.05 (16.07)
0.50 (− 10.29 to 11.29)
One year
post-operative
n = 19
81.00 (14.15)
n = 16
85.63 (13.26)
− 4.63 (− 14.07 to 4.82)
EQ-5D Euroqol five dimension scale, SD standard deviation, CI
confidence interval
Table 6 SF-36 1 year post-operatively. Numbers are mean (SD)
SF-36 domains No synovectomy Synovectomy 95% CI
Physical
functioning
n = 19
60.0 (26.2)
n = 18
74.1 (25.2)
− 14.10
(− 31.29 to 3.08)
Role-physical n = 19
64.5 (33.1)
n = 19
77.6 (29.0)
− 13.20
(− 33.60 to 7.30)
Bodily pain n = 19
59.2 (30.8)
n = 19
72.3 (25.1)
− 13.11
(− 31.62 to 5.41)
General
health
n = 19
66.3 (21.7)
n = 19
61.7 (23.1)
4.55
(− 10.22 to 19.31)
Vitality n = 19
60.2 (18.3)
n = 19
64.5 (23.4)
− 4.28
(− 18.12 to 9.57)
Social
functioning
n = 19
71.1 (24.7)
n = 19
84.9 (23.0)
− 13.82
(− 29.54 to 1.91)
Role-emotional n = 19
86.8 (25.8)
n = 19
82.0 (30.1)
4.82
(− 13.63 to 23.28)
Mental health n = 19
77.9 (18.5)
n = 19
80.9 (17.5)
− 2.96
(− 14.82 to 8.90)
SF-36 Short Form 36, SD standard deviation, CI confidence interval
Table 7 WOMAC scores 1 year post-operatively. Numbers are
mean (SD)
No synovectomy Synovectomy 95% CI
Pain n = 19
78.6 (21.0)
n = 19
83.9 (21.2)
− 5.26 (− 19.20 to 8.67)
Function n = 19
74.3 (19.3)
n = 18
84.6 (16.6)
− 10.29 (− 28.30 to 3.22)
Stiffness n = 18
76.3 (19.5)
n = 17
80.1 (15.3)
− 3.76 (− 15.86 to 8.34)
WOMAC Western Ontario and McMaster Universities Arthritis Index, SD
standard deviation, CI confidence interval
Rankin et al. Pilot and Feasibility Studies  (2018) 4:145 Page 6 of 9
important because a subsequent trial would need to
recruit from multiple centres in order to ensure that
the required number of participants to address the
potential superiority of the synovectomy intervention
would be achieved in a reasonable timeframe. Op-
tions for reducing attrition could also be considered
such as ensuring that provision is made in subse-
quent funding applications for the definitive trial for
additional staff to screen more effectively and pre-
vent drop out from identification of eligibility to par-
ticipant approach and enrolment. A further issue
was some inconsistency at follow-up. This was
mainly due to illegible scores from the patient ques-
tionnaires. This could be mitigated by ensuring add-
itional resources are available to request a further
score from a participant when the initial submission
is not evaluable. A weakness of our study is that the
assessment of the synovium was based on a colour
judgement by the surgeon with no imaging or tissue
sampling to correlate, and therefore, further studies
are already underway at our institution to assess
whether the synovial tissue judged to be macroscop-
ically inflamed correlates with pre-operative imaging
and tissue profiles. A further limitation of our trial
is the small sample size which means that all the re-
sults should be interpreted with caution. Regarding
synovectomy during knee replacement, large
multi-centre surgical studies are warranted to assess
the potential benefits in larger patient cohorts. Fu-
ture trial design should include objective measures
of inflammation both in the joint tissues and system-
ically. For those patients that still suffer from pain
due to residual inflammation following TKA, ad-
junctive therapy in the form of biologics that affect
relevant cellular pathways is an option to be ex-
plored as evidenced by the use of anakinra to
Fig. 3 Patient satisfaction at 1 year, no synovectomy (n = 18). ADL, activities of daily living
Fig. 4 Patient satisfaction at 1 year, synovectomy (n = 17). ADL, activities of daily living
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improve symptomatology in patients with arthrofi-
brosis following TKA [30]. For patients with severe
pain likely related to synovitis but with minimal
changes on the plain radiograph, a combined ap-
proach using arthroscopic synovectomy and medical
therapies may avoid the requirement for joint re-
placement. Defining these treatment strategies will
require close collaboration between orthopaedic sur-
geons and rheumatologists in order to design studies
which will allow us to develop personalised
multi-modal therapeutic for this large group of pa-
tients with an awareness that recruiting to these
studies will require significant amounts of funding
with multi-centre involvement.
Additional file
Additional file 1: Schedule of the trial. (PPT 259 kb)
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